Minimally invasive spine market will surpass $842 million by 2023 as technology swiftly develops: GlobalData

Posted On February 2, 2017 By OrthoSpineNews In Financial, Spine /

February 1, 2017 — The minimally invasive spine (MIS) surgery market, which covers 39 markets, will rise from $512.6 million in 2016 to just over $842 million, representing a compound annual growth rate of 7.4%, according to research and consulting firm GlobalData.

The company’s latest report states that this relatively strong growth will be driven by a global shift towards healthcare treatments performed in outpatient facilities, heightened surgeon interest in incorporating MIS surgical approaches in their practices, and a growing interest in surgical navigation and robotics technologies.

Jennifer Ryan, GlobalData’s Analyst covering Medical Devices, explains: “These factors, coupled with the rising prevalence of degenerative spine diseases and advancements in complementary technologies, is propelling the market forward.”

The global MIS market is controlled by three large multinationals with strong brand name recognition: Medtronic, DePuy, and NuVasive. Other top players include Stryker, Globus Medical, and Zimmer Biomet. These six market leaders boast strong overall spine portfolios and wide-ranging distribution networks, and most offer a full orthopedics platform beyond spine and biologics.

READ THE REST HERE

UPDATE: Medtronic looks to sell $5B medical supplies biz

Posted On February 1, 2017 By OrthoSpineNews In Financial /

FEBRUARY 1, 2017 – BY FINK DENSFORD

Medtronic (NYSE:MDT) is working with advisors for a possible sale of its medical supplies business, according to a Bloomberg report.

The process is reportedly in an early stage, but the Fridley, Minn.-based company has been looking for prospective buyers for the division, which could be worth $5 billion.

The sale could happen in a single deal or through the divestiture of smaller chunks of the business, which sells general medical equipment including monitoring equipment, medical instrumentation, needles and other basic supplies.

A Medtronic spokesman declined to comment, citing the company’s policy on rumors of potential M&A or divestiture plans.

The medical supplies business reported earnings before interest, taxes, depreciation and amortization of approximately $500 million, according to Bloomberg, with the deal slated to snag in the range of 8 to 10 times that number.

READ THE REST HERE

In’Tech Medical Reports 2016 Results

Posted On February 1, 2017 By OrthoSpineNews In Financial /

MEMPHIS, TN (PRWEB) JANUARY 31, 2017

In’Tech Medical SAS, a world leader in Contract Manufacturing of surgical instruments in Orthopedics, reported today 2016 worldwide revenue of $61MM.

“Our organization delivered robust financial results in 2016,” said Laurent Pruvost, President of In’Tech Medical. “Most importantly, we established a global footprint with the acquisition of Ortho Solutions in Malaysia, and have invested over $5MM in new capital equipment to keep developing Manufacturing Expertise across the world.” He added, “Our goal is to continue to increase our capacity, improve our processes and expand our range of services, providing our customers with end-to-end value solutions.”

Beyond the recent development of the Group, Laurent Pruvost is committed to building up In’Tech Medical’s one-stop-shop offering while bringing to market proprietary cutting-edge instruments. In past year, the company launched a new knee impactor, hip reamers and other innovative technologies, which will be on display at upcoming AAOS, March 15-17 2017.

As a testimony to their commitment to providing innovative engineering solutions, In’Tech Medical stepped into the future of Orthopedic surgery at NASS 2016 by launching Wayvio, a new line of connected surgical instruments, with onboard electronics, designed to help OEMs, hospitals and surgery centers optimize logistics, traceability and accountability. More information can be found at http://www.wayvio.com.

With its manufacturing presence in North America, Europe and Asia, In’Tech Medical has established solid foundations for growth and customer satisfaction. The company is tailored to serve regional OEMs, as well as international players looking for global manufacturing solutions.

About In’Tech Medical

Founded in France in 2000, In’Tech Medical is a privately-held company that manufactures surgical instruments and implants. With the company’s recent acquisition of Turner Medical, Inc., the Group is a global leader in orthopedic contract-manufacturing. Powered by a diverse product portfolio, an ability to find solutions to complex engineering challenges, and with close to 500 employees globally, In’Tech Medical is ideally positioned for sustainable growth and personalized customer care.

Vizient, Inc. Shares Results of Post-Election Health Care Survey

Posted On January 30, 2017 By OrthoSpineNews In Financial, Regulatory /

January 30, 2017

IRVING, Texas–(BUSINESS WIRE)–According to Vizient’s post-election survey of member hospital C-suite and hospital pharmacy executives, more than 90 percent are in favor of keeping the protections afforded to patients with preexisting conditions currently included in the Affordable Care Act (ACA). A top concern for the future is lower reimbursements, followed by fewer insured/covered patients.

Vizient, Inc., the nation’s largest member-driven health care performance improvement company, conducted the survey to understand how its member hospitals are reacting to proposed changes by the new Administration to the ACA. The survey also asked executives about their top concerns for the future and their priorities for 2017.

“In reviewing the survey results, central themes come through: uncertainty and concerns about financial viability. There are many open questions about the future of the ACA, and what a repeal and replacement strategy could look like,” said Byron Jobe, president and chief administrative officer for Vizient. “As Congress wrestles with these decisions, it’s important to ensure reimbursement levels are enough to allow hospitals to continue their mission of caring for patients in their communities. Equally important, hospitals must quickly gain a clear understanding of where health policy is heading so they can begin to prepare.”

Top findings from the survey include:

An overwhelming majority of hospital C-Suite leaders (89.5%) and hospital pharmacy executives (96.2%) want to keep the ACA’s protections of patients with pre-existing conditions in place
The majority of hospital C-Suite leaders want to see value-based reimbursement continued in the event that changes are made to the ACA
The top concern for the future of the executives surveyed was lower reimbursement, followed by fewer insured/covered patients
Looking ahead, the leaders surveyed cited reimbursement from Medicare/Medicaid, followed by health policy, as having an influence over hospital merger and acquisition activity
In light of recent price spikes and drug shortages, 55% of hospital executives surveyed said they would like the Trump administration to work with the FDA to fast-track competitive drugs to market
Across all executives surveyed, their top 3 priorities for 2017 were (1) reducing clinical variation across care delivery, (2) migrating toward value-based models and (3) the integration of existing technology systems

“We believe there is broad consensus among hospital leaders that the traditional fee-for-service payment model alone is not sustainable. There have been significant investments made in the migration toward value-based care, and hospitals require a coherent direction in order for these programs to deliver on their promise,” said Jobe. “During this time of uncertainty, executives should focus on factors they can control. Addressing operational efficiency, reducing clinical variation and driving down costs will help executives ensure that their organizations can sustainably weather a changing and potentially leaner operating environment.”

Survey Methodology

The survey was conducted online, with the results based on responses from 222 health care C-suite leaders (CEO, COO, CFO, CMO, CNO, CIO) and hospital pharmacy executives between Dec. 1—14, 2016.

About Vizient, Inc.

Vizient, Inc., the largest member-driven health care performance improvement company in the country, provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership and customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents almost $100 billion in annual purchasing volume. The Vizient brand identity represents the integration of VHA Inc., University HealthSystem Consortium and Novation, which combined in 2015, as well as the recently acquired MedAssets’ Spend and Clinical Resource Management (SCM) segment, which includes Sg2. In 2016, Vizient received a World’s Most Ethical Company designation from the Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit www.vizientinc.com as well as our newsroom, blog, Twitter,LinkedIn and YouTube pages for more information about the company.

Contacts

Vizient, Inc.
Angie Boliver, 972-830-7961
angie.boliver@vizientinc.com

$7.82 Billion Foot and Ankle Devices (Prostheses, Bracing and Support Devices and Orthopedic Implants and Devices) Market 2016 – Forecast to 2025

Posted On January 30, 2017 By OrthoSpineNews In Extremities, Financial /

Dublin, Jan. 26, 2017 (GLOBE NEWSWIRE) — Research and Markets has announced the addition of the “Foot and Ankle Devices Market Analysis & Trends – Product (Prostheses, Bracing and Support Devices and Orthopedic Implants and Devices ), Cause of Injury (Neurological Disorders, Trauma and Diabetes) – Forecast to 2025” report to their offering.

The Global Foot and Ankle Devices Market is poised to grow at a CAGR of around 7.9% over the next decade to reach approximately $7.82 billion by 2025.

Some of the prominent trends that the market is witnessing include increasing numerous sports injuries, growing geriatric population worldwide and increasing new product launches.

Based on product the market is categorized into prostheses, bracing and support devices and orthopedic implants and devices. Prostheses segment is further segmented into Microprocessor-Controlled (MPC) prostheses, Solid Ankle Cushion Heel (SACH) foot, multiaxial prostheses, single-axial prostheses, dynamic response/energy-storing prostheses. Bracing and support devices are further segregated into hinged braces and soft bracing. Orthopedic implants and devices segment is further classified into soft-tissue orthopedic devices, joint implants and fixation devices.

Depending on the cause of injury the market is segmented by neurological disorders, trauma, diabetes and other causes.

This industry report analyzes the global markets for Foot and Ankle Devices across all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

Key Topics Covered:

1 Market Outline

2 Executive Summary

3 Market Overview
3.1 Current Trends
3.1.1 Increasing Numerous Sports Injuries
3.1.2 Growing Geriatric Population Worldwide
3.1.3 Increasing New Product Launches
3.1.4 Growth Opportunities/Investment Opportunities
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness

4 Foot and Ankle Devices Market, By Product
4.1 Prostheses
4.1.1.1 Microprocessor-Controlled (MPC) Prostheses
4.1.1.2 Solid Ankle Cushion Heel (SACH) Foot
4.1.1.3 Multiaxial Prostheses
4.1.1.4 Single-Axial Prostheses
4.1.1.5 Dynamic Response/Energy-Storing Prostheses
4.2 Bracing and Support Devices
4.2.1.1 Hinged Braces
4.2.1.2 Soft Bracing
4.3 Orthopedic Implants and Devices
4.3.1.1 Soft-Tissue Orthopedic Devices
4.3.1.1.1.1 Musculoskeletal Reinforcement Devices
4.3.1.1.1.2 Artificial Tendons & Ligaments
4.3.1.2 Joint Implants
4.3.1.2.1.1 Phalangeal Implants
4.3.1.2.1.2 Ankle Implants (Ankle Replacement Devices)
4.3.1.2.1.3 Subtalar Joint Implants/Subtalar Joint Reconstruction Devices
4.3.1.3 Fixation Devices
4.3.1.3.1.1 Internal Fixation Devices
4.3.1.3.1.1.1.1 Fusion Nails
4.3.1.3.1.1.1.2 Screws
4.3.1.3.1.1.1.3 Plates
4.3.1.3.1.1.1.4 Wires & Pins
4.3.1.3.1.2 External Fixation Devices
4.3.1.3.1.2.1.1 Ring Ankle Fixators
4.3.1.3.1.2.1.2 Unilateral Fixators
4.3.1.3.1.2.1.3 Hybrid Fixators

5 Foot and Ankle Devices Market, By Cause of Injury
5.1 Neurological Disorders
5.2 Trauma
5.3 Diabetes
5.4 Other Causes

6 Foot and Ankle Devices Market, By Geography

7 Leading Companies
7.1 Acumed, LLC
7.2 Arthrex, Inc.
7.3 Extremity Medical, LLC
7.4 Integra Lifesciences Holdings Corporation
7.5 Ossur
7.6 Smith & Nephew PLC.
7.7 Stryker Corporation
7.8 Tornier N.V.
7.9 Wright Medical Technology, Inc.
7.10 Zimmer Biomet Holdings, Inc.
7.11 De Puy Synthes
7.12 Biomet, Inc.
7.13 BioPro, Inc.
7.14 Orthofix Holdings Inc.
7.15 Mondeal Medical Systems GmbH

For more information about this report visit http://www.researchandmarkets.com/research/kphvcg/foot_and_ankle

Vexim: Amendment of the financial agenda for 2017

Posted On January 30, 2017 By OrthoSpineNews In Financial /

Toulouse (France), January 30^th, 2017 (8:30AM CET) –VEXIM (FR0011072602 – ALVXM / PEA-PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, will announce its 2016 Full-Year Results on Wednesday, 22 March, 2017 – before the market opening.

The other dates announced on the original schedule remain unchanged:

Announcement	Date^*
2016 Full-Year Sales	Tuesday January 17^th, 2017
2016 Full-Year Results	Wednesday March 22^nd, 2017
1^st quarter 2017 Sales	Wednesday April 19^th, 2017
Annual General Meeting	Wednesday May 24^th, 2017
2017 Half-Year Sales	Tuesday July 11^th, 2017
2017 Half-Year Results	Thursday September 14^th, 2017
3^rd quarter 2017 Sales	Thursday October 12^th, 2017
	Financial year ended December 31

* Subject to modification. Press releases are distributed either before the financial markets opening, or after the closure

Financial reporting schedule:

2016 Full-Year Results: March 22^nd, 2017^1]

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital^[2] and from BPI public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The company also developed the Masterflow^TM, an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure. The company counts 66 employees, including its own sales teams in Europe and a network of international distributors.

VEXIM has been listed on Alternext Paris since May 2012. For further information, please visit www.vexim.com

SpineJack® ^[3], a revolutionary implant for treating Vertebral Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spinal surgery and worldwide patent protection through to 2029.

Masterflow^TM ², a high-performance orthopedic cement delivery system

The Masterflow^TM is an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure for treating vertebral compression fractures. The device provides a better control of the injection of biomaterials into the spine. A complement of the SpineJack®, the Masterflow^TM stands out for being both easy to use and precise, particularly in its ability to stop the cement delivery instantly without inertia. The Masterflow^TM contributes to reducing pain in patients. Its first sales were recorded in the U.S. in February 2015, and the system has also received the CE marking in February 2015, a mandatory conformity mark for products marketed in Europe.

CONTACTS
VEXIM Vincent Gardès, CEO José Da Gloria, Chief Financial Officer investisseur@vexim.com Tél. : +33 5 61 48 48 38		PRESS ALIZE RP Caroline Carmagnol / Wendy Rigal vexim@alizerp.com Tél. : +33 1 44 54 36 66 Tél. : +33 6 48 82 18 94
	Name : VEXIM ISIN code : FR0011072602 Ticker : ALVXM

Alphabet’s life science spinoff raises $800M from Singapore investor

Posted On January 27, 2017 By OrthoSpineNews In Financial /

Luke Stangel, Contributing writer – Jan 26, 2017

Verily Life Sciences, one of the startups spun out of Alphabet, disclosed on Thursday it has closed an $800 million investment from Singapore-based Temasek, an investment company that recently landed in the Bay Area with plans to expand its holdings in North America.

Verily, previously known as Google Life Sciences, says it’ll get the majority of the money in the coming days, with the remainder coming later this year. Temasek will take a minority stake in the company and get a seat on Verily’s board.

The investment marks Alphabet’s latest attempt to reduce the financial risk inherent in its more experimental business units like Verily. In the past, a spinoff like Verily might have instead asked its corporate parent for the investment.

Around this time last year, Verily partnered with Johnson & Johnson to create a new robotic surgery startup called Verb. A few months later, it announced a $715 million joint venture with Glaxosmithkline to create a new bioelectronics medicine company called Galvani Bioelectronics. In September, Verily announced it was creating a $500 million joint venture with Sanofi called Onduo.

READ THE REST HERE

Stryker Maintains Growth Momentum With Strategic M&A, Robotic Surgery Roll-Out

Posted On January 27, 2017 By OrthoSpineNews In Financial /

January 26, 2017 – By Suzanne Hodsden

Stryker Corporation delivered its fourteenth straight quarter with double-digit growth in net sales in 2016’s fourth quarter, building on the rest of the year’s momentum and staggered roll-out of MAKO surgical robots, said CEO Kevin Lobo. Despite its pair of billion-dollar acquisitions — Sage Products and Physio-Control — Lobo said Stryker is “actively” seeking new strategic growth through acquisitions.

Despite “tough” year-over-year comparisons, Lobo reported in an earnings call that Q4 represented 2016’s highest growth quarter, with 16.2 percent growth across all of Stryker’s core businesses: orthopedics, medsurg, and neurotechnology and spine. The company experienced its largest sales bump in medsurg, with a staggering 31 percent for the quarter.

Earlier in 2016, Stryker completed a series of acquisitions, including a $2.78 billion deal for Sage Products — manufacturer of disposable hospital supplies designed to prevent hospital-related infections — and a $1.28 billion deal for Physio-Control, with its portfolio of emergency services equipment. Despite heavy R&D investment in both segments, the two acquisitions delivered 11.8 percent and 7.4 percent Q4 growth, respectively.

“We continue to complete value creating acquisitions, our globalization efforts are bearing fruit, and we are also building capability to deliver consistent leveraged earnings,” said Lobo.

Moving forward, Lobo said that he has not ruled out further investment and growth opportunities, and that the volume of M&A activity in 2016 is not indicative of a slowdown in 2017. While certain segments took on the job of the two large acquisitions, other divisions “certainly have the bandwidth” to accommodate additional deals.

READ THE REST HERE

AdvaMed Names New Head of Orthopedics Sector

Posted On January 25, 2017 By OrthoSpineNews In Financial, Regulatory /

By Advanced Medical Technology Association | January 24, 2017

The Advanced Medical Technology Association (AdvaMed) has announced that Juan-José Gonzalez, president, U.S. DePuy Synthes, part of the Johnson & Johnson Family of Companies, has been named head of the organization’s Orthopedics Sector. In this role, Gonzalez will help lead and coordinate the regulatory and reimbursement ad-vocacy priorities that particularly impact AdvaMed’s orthopedic member companies.

As head of U.S. DePuy Synthes, Gonzalez leads a more than $5 billion orthopedic business and is responsible for all strategic and commercial activities. In his decade at Johnson & Johnson, he has held a number of management roles of increasing responsibility, most recently serving as president, DePuy Synthes Europe, Middle East and Africa (EMEA), where he led the team driving innovation and growth across the EMEA region by leveraging a broad port-folio to address customer needs in the changing market environment. Gonzalez also has a passion and successful track record for driving talent development within his organization and serves as an ongoing mentor to many within Johnson & Johnson.

Gonzalez has an engineering degree from the University of Lima, Peru; an M.B.A. in marketing and corporate finance from the University of Notre Dame; and a master’s degree in technology from Columbia University.

“With his breadth of experience and knowledge of global markets, Juan-José is an excellent choice to lead AdvaMed’s Orthopedics Sector and to advocate worldwide for patient access to needed mobility technologies,” said AdvaMed senior vice president Tara Federici, staff lead for the sector.

Priority issues for the association’s Orthopedic Sector include:

Working with key stakeholders on the design, devel-opment and maintenance of an effective orthopedic device registry in the U.S.; and
Ensuring the value of orthopedic implants is captured in new payment methodologies.

– See more at: http://www.odtmag.com/contents/view_breaking-news/2017-01-24/advamed-names-new-head-of-orthopedics-sector#sthash.ek3eb20Q.dpuf

Arthroscopy market to surpass $5.7 billion by 2023 as sports injuries are on the rise, says GlobalData

Posted On January 25, 2017 By OrthoSpineNews In Financial, Sports Medicine /

25 January 2017

The arthroscopy market, which covers 39 countries and includes implant and capital equipment, is set to rise from $4.19 billion in 2016 to $5.73 billion by 2023, representing a compound annual growth rate (CAGR) of 4.6%, according to research and consulting firm GlobalData.

The company’s latest report states that this growth will be driven by the rising prevalence of sports injury, which is growing at a CAGR of 6.3% and is primarily caused by intense and repetitive training in major markets like the US and China. Other drivers include rising obesity rates, an aging population and the trend towards more innovative minimally-invasive techniques, reducing cost and recovery time for patients.

Tobe Madu, MSc, GlobalData’s Analyst covering Medical Devices, explains: “Sports medicine technology is built on minimally-invasive arthroscopic implants and equipment, and these will continue to drive the market, as well as other orthopedic segments. As both a technique-driven and an implant-based field, there are arthroscopic products continuously entering the market for difficult-to-access joints, and smaller implants for smaller repairs.

“Materials development has been a key interest for physicians, as they look for more durable and biocompatible implant materials. For example, knee cartilage injuries have driven the development of products for meniscal repair, while anterior cruciate ligament and posterior cruciate ligament injuries have inspired biocomposite and bioresorbable interference screws.”

While healthcare spending as reflected by reimbursement rates is expected to go down globally, the market outlook remains strong in western countries, as substantial growth in new indications will drive up procedure numbers. Meanwhile, countries such as Brazil, China, and India, will continue to see adoption of arthroscopic products as surgeon training improves and newer economical products are introduced in the market, according to GlobalData.

Madu continues: “As disposable surgical products turn into commodities, buyer decision will become increasingly price sensitive. Despite this development, market leaders such as Arthrex and Stryker, who maintain a culture of innovation and service while delivering cost-effective products, will stay ahead of competitors.

“The most significant area of growth is in hip arthroscopy, where global revenue is expected to increase by a CAGR of 14.5% during the forecast period.”

Editor’s notes

– Comments provided by Tobe Madu, MSc, GlobalData’s Analyst covering Medical Devices.

– Information based on GlobalData’s report: MediPoint: Sports Medicine – Global Analysis and Market Forecasts.

– This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts. The 39 major markets include the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China, India, South Korea, Australia, Canada, Mexico, Russia, Austria, Belgium, Czech Republic, Denmark, Finland, Greece, Hungary, Ireland, Netherlands, Norway, Poland, Portugal, Sweden, Switzerland, Turkey, Taiwan, New Zealand, Argentina, Chile, Egypt, Israel, Saudi Arabia, South Africa, and the United Arab Emirates.

– For guidelines on how to cite GlobalData, please see: https://healthcare.globaldata.com/media-center/quoting-globaldata

About GlobalData

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information

Please get in contact if you have any questions about this or other GlobalData products. Analysts are available to comment. Contact the GlobalData press office +44 (0)161 359 5822 or email pr@globaldata.com